Ipsen

This study tests a daily pill called elafibranor in 18 Japanese adults with primary biliary cholangitis (PBC), a rare liver disease that can lead to cirrhosis or transplant. Participants had an inadequate response to standard treatment. The main goal is to see if elafibranor impr…

This study tests a drug called elafibranor in 68 adults with primary sclerosing cholangitis (PSC), a rare liver disease that damages bile ducts. The main goal is to check the drug's safety and side effects compared to a placebo. Researchers will also measure changes in blood test…

This study follows 311 adults with advanced kidney cancer who are receiving a combination of two drugs, cabozantinib and nivolumab, as their first treatment. Researchers are tracking how long patients live and how long the cancer stays under control in everyday medical practice. …

This study looks at how the drug odevixibat affects long-term health in people with a rare liver disease called PFIC. Researchers compared patients who took odevixibat in earlier trials to similar patients who did not receive the drug. The goal is to see if odevixibat helps avoid…

This study looks at how well the drug tazemetostat works in adults with follicular lymphoma, a slow-growing blood cancer, that has returned or not responded after at least two prior treatments. Participants take tazemetostat as prescribed by their doctor in routine care. The stud…

This study tests a daily pill called elafibranor in adults with primary biliary cholangitis (PBC) who did not get enough help from standard treatment. The goal is to see if elafibranor can bring a key liver enzyme (ALP) back to normal levels, which may slow liver damage. About 69…

This study tests a new drug called elafibranor for people with primary biliary cholangitis (PBC), a rare liver disease that can lead to scarring and liver failure. The trial includes 161 adults who did not get better with or could not take the standard medicine. The goal is to se…

This study tests whether Dysport injections can prevent chronic migraine in adults who have headaches at least 15 days per month. About 759 participants will receive either Dysport or a placebo injected into head, neck, and shoulder muscles. The goal is to see if Dysport reduces …

This study tests whether Dysport, a botulinum toxin type A injection, can prevent episodic migraines (fewer than 15 headache days per month) in adults. About 751 participants will receive either Dysport or a placebo injected into head, neck, and shoulder muscles over 24 weeks, fo…

This study is testing a new medication called IPN10200 to see if it can safely improve the appearance of moderate to severe frown lines, forehead lines, and crow's feet in adults. About 727 participants will receive different doses of the drug or a placebo to find the best dose. …

This study follows 450 premenopausal women with early-stage hormone-positive breast cancer to see how their quality of life changes during treatment with triptorelin and other hormone therapies. Researchers will also track treatment effectiveness, safety, and how well patients fo…

This study follows 113 adults with upper limb spasticity from brain injuries like stroke or trauma, along with their caregivers. Researchers measure how abobotulinumtoxin A injections affect caregiver burden, patient disability, and daily function in routine medical practice. The…

This study looks at how the drug cabozantinib (Cabometyx®), given alone or with nivolumab, is actually used by doctors and patients in Belgium for advanced or metastatic kidney cancer. It does not test a new treatment but instead observes 150 adults to understand dosing patterns,…

This study follows about 1,000 adults who have had their first stroke to see how many develop muscle stiffness (spasticity) within a year. Researchers want to create a standard way to monitor this condition so doctors can catch it early. Participants must be 18–90 years old and h…

This study watches how adults with advanced kidney cancer handle the drugs cabozantinib (alone or with nivolumab) as their first treatment. It does not test new treatments but tracks real-life side effects, dose changes, and treatment stops. The goal is to learn how these drugs a…